期刊文献+

子宫内膜增生症患者米非司酮治疗前后子宫内膜组织血管内皮生长因子的表达和意义 被引量:8

The change and clinical value of vascular endothelial growth factor and microvessel density in the mifepris-tone treated endometrial hyperplasia
下载PDF
导出
摘要 目的探讨米非司酮抑制子宫内膜增生的机制。方法37例子宫内膜增生症(不伴非典型增生)患者,连续口服米非司酮(剂量10mg/a)治疗3个月,刮取治疗前、后子宫内膜组织,进行自身对比;另取10名正常增殖期子宫内膜组织作为对照组进行比较。采用免疫组织化学二步法分别检测血管内皮生长因子(VEGF)及微血管密度(MVD),应用CD34抗体标记微血管并测量MVD。结果子宫内膜增生症治疗前腺上皮VEGF表达(129.6±60.0)略高于正常增殖期子宫内膜(88.5±0.7),差异无统计学意义(P〉0.05)。米非司酮治疗后(61.7±21.8)与治疗前相比,子宫内膜VEGF表达明显下降,差异有统计学意义(P〈0.05)。子宫内膜增生症MVD(16.3±1.9)略高于正常增殖期子宫内膜(11.64-3.8),差异无统计学意义(P〉0.05)。米非司酮治疗后(10.5±2.1)与治疗前相比,MVD明显下降,差异有统计学意义(P〈0.05)。结论米非司酮使子宫内膜VEGF减少从而抑制血管形成,可能是米非司酮抑制子宫内膜增生的机制之一。 Objective To investigate the mechanism of mifepristone in suppressing the emdometrial hypoerplasia. Methods Thirty seven cases with endometrial hyperplasia (without atypical hyperplasia) were pathologically evaluated for the endometrial hyperplasia before and after 3 months' treatment with oral mifepristone ( 10 mg,/d). Normal endometrial iissues in proliferating phase from other 10 healthy women were also evaluated as control. Twostep immunohistochemical staining was adopted to detected the levels of vascular endohtelial growth factor (YEGF) and microvessel density (MVD). Antibody against CD34 was used as a marker for microvessels. Results VEGF expressed in untreated medometrial hyperplasia was slight higher than that in normal proliferative endometrium [ ( 129. 6 ± 60.0) vs ( 88.5 ± 0. 7) 1, but the difference was not significant ( P 〉 0.05 ). Compared with that before treatment, VEGF was significantly decreased after mifepristone treatment [ (61.7 ± 21.8 ) vs ( 129.6 ± 60. O) ] (P 〈 0. 05). MVD in endometrial hyperplasia MVDis slightly higher than that in normal proliferative endometrium ( 16. 3±1.9) vs ( 11.6 ± 3.8 ) ( P 〉 0.05 ). However, MVD in endometrial hyperplasia was significantly decreased after mifepristone treatment [ ( 10. 5 ±2. 1 ) vs ( 16. 3 ± 1.9) ] (P 〈 O. 05). Conclusion Mifepristone reduces an- giogenesis in endometrium by supI^ressing VEGF expression, which may be one of its mechanism of inhibiting the endometrial hyperplasia.
出处 《中国医药》 2012年第3期348-350,共3页 China Medicine
关键词 子宫内膜增生症 米非司酮 血管内皮生长因子 微血管密度 Endometrial hyperplasia Mifepristone Vascular endothelial growth factor (VEGF) Microvessel density (MVD)
  • 相关文献

参考文献12

  • 1Huaqing Wen,Jihong Deng,Ping Pu,et al. The effects of vascula r endothelia I growth factor and microvesseL density in the fib~x~myoma uteri. Chinese-German Journal OF Clinical Oncology, 2008, 7 (10) :593-596.
  • 2Folkman J. Seminars in Medicine of the Beth Israel Hospital, Bos- ton. Clinical applications of research on angiogenesis. N Engl J Med, 1995,333 (26) : 1757-1763.
  • 3张凌云,王玉涛.米非司酮治疗子宫肌瘤60例分析[J].中国误诊学杂志,2006,6(14):2751-2752. 被引量:4
  • 4Fanelll M,Locopo N, Gattuso D, et al. Assessment of tumor vaseu- larization: immunohistochemical and non-invasive methods, lnt J Biol Markers, 1999,14 (4) :218-231.
  • 5Yano S, Goto H, Yamamoto A, et al. Angiogenesis in the progression of lung cancer. Intern Med,2003,42 ( 3 ) :305-309.
  • 6Huang JC, Liu DY, Dawood MY. The expression of vascular erldo- thelial growth factor isoforms in cultured lmman endometrialstromal ceils and its regulation by 17beta-oestradiol. Mol Hum Reprod, 1998,4(6) :603-607.
  • 7Greb RR, Heikinheimo O, Williams RF, et al. Vascular endothelial growth factor in primate endometrium is regulated by oestrogen-re- ceptor and progesterone-receptor 1997,12 (6) : 1280-1292.
  • 8Johannisson E, Oberholzer M, Swahn ML, et al. Vascular changes in the human endometrium following the administration of the proges- terone antagonist RU 486. Contraception, 1989,39 ( 1 ) : 103 - 117.
  • 9Sugino N,Kashida S, Karube-Harada A, et al. Expression of vascu- lar endothelial growth factor (VEGF) and its receptors in human endometrium throughout the menstrual cycle and in early pregnan- cy. Reproduction ,2002,123 ( 3 ) :379-387.
  • 10Perrot-Applanat M, Ancelin M, Buteau-Lozano H, et al. Ovarian steroids in endometrial angiogenesis. Steroids, 2000,65 ( 10-11 ) : 599-603.

二级参考文献4

共引文献3

同被引文献68

引证文献8

二级引证文献63

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部